Keeley Teton Advisors LLC Has $930,000 Stock Position in Agilent Technologies, Inc. (NYSE:A)

Keeley Teton Advisors LLC cut its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 5.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,924 shares of the medical research company’s stock after selling 403 shares during the period. Keeley Teton Advisors LLC’s holdings in Agilent Technologies were worth $930,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in A. Guggenheim Capital LLC increased its position in Agilent Technologies by 3.5% during the fourth quarter. Guggenheim Capital LLC now owns 9,804 shares of the medical research company’s stock worth $1,317,000 after acquiring an additional 332 shares during the period. Rossby Financial LCC bought a new position in shares of Agilent Technologies during the fourth quarter worth approximately $228,000. Aware Super Pty Ltd as trustee of Aware Super acquired a new stake in shares of Agilent Technologies in the fourth quarter valued at approximately $16,064,000. Canada Post Corp Registered Pension Plan bought a new stake in shares of Agilent Technologies in the fourth quarter valued at approximately $5,092,000. Finally, Synovus Financial Corp grew its position in Agilent Technologies by 7.7% during the fourth quarter. Synovus Financial Corp now owns 1,934 shares of the medical research company’s stock worth $260,000 after buying an additional 139 shares in the last quarter.

Insider Buying and Selling

In related news, VP Rodney Gonsalves sold 1,908 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the sale, the vice president now directly owns 21,786 shares in the company, valued at $2,657,456.28. This represents a 8.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Daniel K. Podolsky sold 1,819 shares of the firm’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $116.46, for a total transaction of $211,840.74. Following the transaction, the director now owns 35,737 shares of the company’s stock, valued at approximately $4,161,931.02. The trade was a 4.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,638 shares of company stock worth $731,229 in the last ninety days.

Agilent Technologies Stock Performance

Shares of Agilent Technologies stock opened at $102.80 on Thursday. The company’s 50 day moving average price is $121.16 and its two-hundred day moving average price is $133.12. The firm has a market capitalization of $29.31 billion, a P/E ratio of 23.63, a P/E/G ratio of 2.90 and a beta of 1.19. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $155.35.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. On average, equities analysts forecast that Agilent Technologies, Inc. will post 5.55 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be issued a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.96%. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.76%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on A. Barclays cut their target price on Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Robert W. Baird cut their price objective on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Citigroup raised their target price on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a report on Thursday, December 19th. TD Cowen upped their price target on shares of Agilent Technologies to $135.00 and gave the stock a “buy” rating in a report on Thursday, April 10th. Finally, StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $146.25.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.